FDA Clears IND for IBI363 in Squamous Non–Small Cell Lung Cancer
Developers will now initiate the phase 3 MarsLight-11 trial of IBI363 among patients with immunotherapy-resistant squamous non–small cell lung cancer.
Previous Post
Income and Assets of Medicare Beneficiaries in 2024
Next Post
Nursing Power Can Change the World
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago